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sibility) are likely to be highly proﬁtable from a societal
point of view.
NEUROLOGICAL DISORDERS/MIGRAINE—
Quality of Life Studies
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OBJECTIVE: The purpose of this study was to investi-
gate the validity and reliability of Singaporean language
versions (English and Chinese) of the EQ-5D self-report
questionnaire (EQ-5D) in patients with Parkinson’s
disease. METHODS: Patients with Parkinson’s disease
recruited from a patient support group and a hospital out-
patient clinic completed a questionnaire containing the
EQ-5D and the Parkinson’s disease questionnaire (PDQ-
39) twice in a 2-week period. Test-retest reliability was
assessed for EQ-5D items, utility index and visual analog
scale (EQ-VAS) using Cohen’s kappa or intraclass corre-
lation coefﬁcients (ICC). Construct validity of EQ-5D
utility and EQ-VAS scores was assessed using Spearman’s
rank correlations between EQ-5D and PDQ-39 summary
index (PDQ-39SI) scores. RESULTS: One hundred ﬁfty
subjects (English-speaking: n = 87) completed baseline
and 106 subjects (English-speaking: n = 68) completed
follow-up questionnaires (median interval: 12 days).
Kappa values of EQ-5D items ranged from 0.58 to 0.75
(English version) and from 0.38 to 0.55 (Chinese version).
ICC values for utility/ EQ-VAS scores were 0.78/ 0.83
(English version) and 0.62/ 0.72 (Chinese version) respec-
tively. Spearman’s correlation coefﬁcients between utility/
EQ-VAS scores and the PDQ-39SI were -0.66/ -0.45
(English version) and -0.76/ -0.44 (Chinese version)
respectively (p < 0.001 for all). CONCLUSION: Both Sin-
gaporean English and Chinese EQ-5D versions appear to
be valid and reliable outcome measures for Singaporeans
with Parkinson’s disease.
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OBJECTIVES: To investigate quality of life at application
piribedil in patients with idiopathic Parkinson’ Disease
(PD). METHODS: A total of 43 patients with PD (men
age: 67.3 ± 5.4 years, duration of disease: 4.3 ± 2.8 years)
were investigated during 2 years. They were observed
during 1 year with basic treatment and during 1 years
after addition piribedil (non-ergot Dopamine Agonist) to
basic treatment. To estimate efﬁcacy of treatment we used
Uniﬁed Parkinson’s Disease Rating Scale (UPDRS). To
evaluate quality of life we used the disease-speciﬁc
Health-Related Quality of Life scale Parkinson Disease
Questionnaire (PDQ-39). RESULTS: During the 1-year
follow-up before piribedil treatment patients had minor
clinical deterioration and deterioration of quality of life
because illness progressed. Early PD patients showed
increase at 6.3% of UPDRS values and 9.9% of PDQ-39
values (p < .05) per 1 year, advanced PD patients showed
increase at 5.7% of UPDRS values and 5.4% of PDQ-39
values (not signiﬁcant) per 1 year. Addition of piribedil in
early PD patients resulted in improvement at 8.9% of
UPDRS values per one year (p < .01) and 10.7% of PDQ-
39 values (p < .001). The most essential were changes in
the following subscales of PDQ-39: “Mobility”, “Activi-
ties of Daily Living”, “Emotional well being” (p < .01)
and “Stigma” (p < .05). Changes in the others subscales
were not signiﬁcant. Advanced PD patients also demon-
strated positive changes on piribedil treatment: 7.0%
decrease of UPDRS values (p < .05) per one year and
7.7% of PDQ-39 values (p < .05) per 1 year. Patients had
signiﬁcant improvement only in subscales “Mobility” and
“Activities of Daily Living” (p < .05). CONCLUSIONS:
Addition of piribedil improves quality of life in PD
patients. More expressed improvements in quality of life
is observed in early PD patients in Russia.
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The management of a chronic disease must integrate the
needs induced by the disease on the patient’s surround-
ings. OBJECTIVE: The objective of the COMPAS study
is to assess the socio-economic consequences on the daily
life of the spouse of a patient diagnosed with Parkinson’s
disease and to identify their worries and needs.
METHODS: Self-administered questionnaires, created on
the basis of interviews with the spouses of parkinson
patients, were sent to general practitioners, neurologists
as well as to members of patients’ associations (France-
parkinson), who then distributed them to the families
concerned. RESULTS: The results concerned a popula-
tion of 1013 spouses. Patients had been diagnosed since
10.4 years on average at the age of 58.8 years old. The
spouse is often a woman (66%), retired (68%) and more
than 70 years old (40%). She is the only person looking
after the patient (49%). She spends on average 7.5 hours
per day in taking care of the patient. This high level of
involvement greatly modiﬁes her daily life : speciﬁc organ-
